{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:17:09Z","timestamp":1793661429132,"version":"4.5.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.diabres.2026.113333","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:29:52Z","timestamp":1779146992000},"page":"113333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"237","author":[{"given":"Po-Lung","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3608-1394","authenticated-orcid":false,"given":"Hua-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113333_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabres.2026.113333_b0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bph.15485","article-title":"Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands","volume":"179","author":"Tanday","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabres.2026.113333_b0015","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2026.113333_b0020","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management","volume":"6","author":"Holst","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.diabres.2026.113333_b0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.diabres.2026.113333_b0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the Side Effects of GLP-1 Receptor Agonist: to Ensure its Optimal Positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113333_b0035","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.diabres.2026.113333_b0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.diabres.2026.113333_b0045","doi-asserted-by":"crossref","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Frey C, Etminan M. Risk of Hair Loss with Semaglutide for Weight Loss. medRxiv. 2025:2025.02.23.25322568.","DOI":"10.1101\/2025.02.23.25322568"},{"key":"10.1016\/j.diabres.2026.113333_b0050","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113333_b0055","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113333_b0060","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113333_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years","volume":"181","author":"Danne","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.diabres.2026.113333_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EC-16-0113","article-title":"Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential","volume":"6","author":"Nylander","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.diabres.2026.113333_b0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.15605\/jafes.033.02.02","article-title":"The Multicenter, open-label, observational LEAD-Ph study: real-world safety and effectiveness of liraglutide in filipino participants with type 2 diabetes","volume":"33","author":"Jimeno","year":"2018","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"10.1016\/j.diabres.2026.113333_b0080","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113333_b0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113333_b0090","doi-asserted-by":"crossref","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705\u2013719.","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"10.1016\/j.diabres.2026.113333_b0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/bmjnph-2023-000733","article-title":"Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control","volume":"6","author":"Shand","year":"2023","journal-title":"BMJ Nutr Prev Health"},{"key":"10.1016\/j.diabres.2026.113333_b0100","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2026.113333_b0105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-8587(24)00150-5","article-title":"Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial","volume":"12","author":"Eckard","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113333_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2026.113333_b0115","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/ijd.17971","article-title":"Association between androgenetic alopecia and glucagon-like peptide-1 receptor treatment in type 2 diabetes mellitus patients: a retrospective cohort study","volume":"64","author":"Singal","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.diabres.2026.113333_b0120","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/dom.16376","article-title":"Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database","volume":"27","author":"Kim","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113333_b0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.8605","article-title":"A Retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies","volume":"24","author":"Daniel","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.diabres.2026.113333_b0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","article-title":"Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin","volume":"134","author":"List","year":"2006","journal-title":"Regul Pept"},{"key":"10.1016\/j.diabres.2026.113333_b0135","article-title":"Research progress in the treatment of non-scarring alopecia: mechanism and treatment","volume":"16","author":"Guo","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113333_b0140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","article-title":"Telogen Effluvium - a review of the science and current obstacles","volume":"101","author":"Chien Yin","year":"2021","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.diabres.2026.113333_b0145","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1007\/s11695-025-07903-8","article-title":"Hair loss and metabolic and bariatric surgery: an updated systematic review and meta-analysis","volume":"35","author":"Taghizadeh","year":"2025","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabres.2026.113333_b0150","doi-asserted-by":"crossref","unstructured":"Smolarczyk K, Meczekalski B, Rudnicka E, Suchta K, Szeliga A. Association of Obesity and Bariatric Surgery on Hair Health. Medicina (Kaunas). 2024;60.","DOI":"10.3390\/medicina60020325"},{"key":"10.1016\/j.diabres.2026.113333_b0155","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.70125","article-title":"Alopecia and semaglutide: connecting the dots for patient safety","volume":"24","author":"Haykal","year":"2025","journal-title":"J Cosmet Dermatol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:36:29Z","timestamp":1780634189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0168822726002536"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113333","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113333"}}